Results 11 to 20 of about 5,967 (167)

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects

Pathology and Oncology Research, 2022
Targeting molecular alterations has been proven to be an inflecting point in tumor treatment. Especially in recent years, inhibitors that target the tyrosine receptor kinase show excellent response rates and durable effects in all kind of tumors that ...
Vasiliki Siozopoulou, Vasiliki Siozopoulou, Elly Marcq, Koen De Winne, Koen Norga, Gertjan Schmitz, Valerie Duwel, Philippe Delvenne, Evelien Smits, Evelien Smits, Patrick Pauwels, Patrick Pauwels   +11 more
doaj   +4 more sources

NTRK fusions are extremely rare in bone tumours [PDF]

Histopathology, 2021
AimsBecause of the efficacy of tropomyosin receptor kinase (Trk) inhibitor therapy in tumours with rearrangements of the neurotrophic tyrosine kinase receptor genes (NRTK genes), there has been a surge in demand for NTRK fusion screening. To date, most studies involving mesenchymal tumours have focused on soft tissue tumours, and data on bone tumours ...
Suk Wai Lam, Inge H Briaire‐de Bruijn, Tom van Wezel, Arjen H G Cleven, Pancras C W Hogendoorn, Anne‐Marie Cleton‐Jansen, Judith V M G Bovée   +6 more
openaire   +4 more sources

Multi-Cancer Genome Profiling for Neurotrophic Tropomyosin Receptor Kinase (NTRK) Fusion Genes: Analysis of Profiling Database of 88,688 Tumors [PDF]

Cancers
Masakazu Yashiro, Daiki Imanishi, Koji Maruo   +2 more
exaly   +2 more sources

NTRK Gene Fusion Detection in Atypical Spitz Tumors [PDF]

International Journal of Molecular Sciences, 2021
Atypical Spitz tumors (AST) deviate from stereotypical Spitz nevi for one or more atypical features and are now regarded as an intermediate category of melanocytic tumors with uncertain malignant potential. Activating NTRK1/NTRK3 fusions elicit oncogenic events in Spitz lesions and are targetable with kinase inhibitors.
Rocco Cappellesso, Filippo Nozzoli, Federica Zito Marino, Sara Simi, Francesca Castiglione, Vincenzo De Giorgi, Carlo Cota, Rebecca Senetta, Giosuè Scognamiglio, Anna Maria Anniciello, Anna Maria Cesinaro, Mario Mandalà, Andrea Gianatti, Maria Gabriella Valente, Barbara Valeri, Angela Rita Sementa, Costantino Ricci, Barbara Corti, Giandomenico Roviello, Angelo Paolo Dei Tos, Renato Franco, Daniela Massi   +21 more
openaire   +3 more sources

A review of NTRK fusions in cancer

Annals of Medicine & Surgery, 2022
The family of the neurotrophic tropomyosin kinase receptors (NTRK or TRK) is a part of the transmembrane tyrosine kinases responsible for neuronal development. The members of this receptor family are TRKA, TRKB and TRKC and they are encoded by the genes NTRK1, NTRK2 and NTRK3.
Manea, Cristina Alexandra, Badiu, Dumitru Cristinel, Ploscaru, Ioan Cristian, Zgura, Anca, Bacinschi, Xenia, Smarandache, Catalin Gabriel, Serban, Dragos, Popescu, Cristian Gabriel, Grigorean, Valentin Titus, Botnarciuc, Vladimir   +9 more
openaire   +2 more sources

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects [PDF]

Diagnostics, 2021
Tropomyosin receptor kinase (TK) is encoded by the neurotrophic tyrosine receptor kinase genes (NTRK) 1, 2, and 3, whose activation plays an important role in cell cycle proliferation and survival. Fusions of one of these genes can lead to constitutive activation of TRK, which can potentially be oncogenic.
Vasiliki Siozopoulou, Evelien Smits, Koen De Winne, Elly Marcq, Patrick Pauwels   +4 more
openaire   +5 more sources

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

Frontiers in Oncology, 2022
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%.
Fangfang Liu, Yuxuan Wei, Huan Zhang, Jizong Jiang, Peng Zhang, Qian Chu   +5 more
doaj   +1 more source

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China

npj Precision Oncology, 2023
Neurotrophic tyrosine kinase (NTRK) fusions involving NTRK1, NTRK2, and NTRK3 were found in a broad range of solid tumors as driver gene variants. However, the prevalence of NTRK fusions in Chinese solid tumor patients is rarely reported.
Yujun Xu, Xiaoliang Shi, Weifeng Wang, Lin Zhang, Shinghu Cheung, Marion Rudolph, Nicoletta Brega, Xiaowei Dong, Lili Qian, Liwei Wang, Shaohua Yuan, Daniel Shao Weng Tan, Kai Wang   +12 more
doaj   +1 more source

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

npj Precision Oncology, 2021
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers in solid tumours. This study aimed to interrogate a large real-world database of comprehensive genomic profiling data to describe the genomic landscape and prevalence
C. B. Westphalen, M. G. Krebs, C. Le Tourneau, E. S. Sokol, S. L. Maund, T. R. Wilson, D. X. Jin, J. Y. Newberg, D. Fabrizio, L. Veronese, M. Thomas, F. de Braud   +11 more
doaj   +1 more source

MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas

Frontiers in Oncology, 2021
To gain insight into the clinicopathologic profile of colorectal carcinomas harboring oncogenic NTRK fusions based on eastern populations as well as make the best testing algorithm for the screen, we use pan-Trk immunohistochemistry (IHC), fluorescence ...
Yao Fu, Zheng Li, Fuping Gao, Jun Yang, Hongyan Wu, Biao Zhang, Xiaohong Pu, Xiangshan Fan   +7 more
doaj   +1 more source